NCT06171750solid tumorsANK-101tolododekin alfa
… blood-based predictive biomarkers.Methods In a Phase 1 study ( NCT06171750), ANK-101 was administered IT every 3 weeks for up to 8 cycles …
1articles mentioning funders
1funder mentions
1distinct funders extracted
0%of mentions human-reviewed
Active filtersEntity: NCT06171750 ×
NCT06171750
This funder is selected. Its supporting articles are shown below.